Get the Stockscreener App
17.59
0.23%
-0.04
Pre-market:
17.60
0.01
+0.06%
Overview
News
Price History
Option Chain
Financials
Why BAX Down?
Discussions
Forecast
Stock Split
Dividend History
Baxter International Inc stock is traded at $17.59, with a volume of 5.76M.
It is down -0.23% in the last 24 hours and up +1.09% over the past month.
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
See More
Previous Close:
$17.63
Open:
$17.74
24h Volume:
5.76M
Relative Volume:
0.59
Market Cap:
$9.08B
Revenue:
$11.24B
Net Income/Loss:
$-900.00M
P/E Ratio:
-10.48
EPS:
-1.679
Net Cash Flow:
$323.00M
1W Performance:
+5.84%
1M Performance:
+1.09%
6M Performance:
-22.92%
1Y Performance:
-38.02%
1-Day Range:
$17.57
$18.05
1-Week Range:
$16.81
$18.05
52-Week Range:
$15.73
$32.68
Baxter International Inc Stock (BAX) Company Profile
Name
Baxter International Inc
Sector
Industry
Phone
(224) 948-2000
Address
ONE BAXTER PARKWAY, DEERFIELD, IL
Compare BAX vs ISRG, BDX, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BAX
Baxter International Inc
|
17.59 | 8.85B | 11.24B | -900.00M | 323.00M | -1.679 |
ISRG
Intuitive Surgical Inc
|
467.22 | 160.05B | 10.06B | 2.88B | 2.49B | 7.876 |
BDX
Becton Dickinson Co
|
155.73 | 43.87B | 21.92B | 1.76B | 2.63B | 6.1223 |
ALC
Alcon Inc
|
79.94 | 38.02B | 10.40B | 980.00M | 1.61B | 1.9749 |
MDLN
Medline Inc
|
47.67 | 37.01B | 28.43B | 1.16B | 1.26B | 1.4457 |
RMD
Resmed Inc
|
230.69 | 33.34B | 5.40B | 1.49B | 1.78B | 10.12 |
Baxter International Inc Stock (BAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-31-25 | Downgrade | Argus | Buy → Hold |
| Aug-04-25 | Downgrade | Stifel | Buy → Hold |
| Aug-01-25 | Downgrade | Goldman | Buy → Neutral |
| Feb-26-25 | Resumed | Goldman | Buy |
| Feb-24-25 | Upgrade | Argus | Hold → Buy |
| Feb-20-25 | Resumed | Barclays | Overweight |
| Jul-15-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| May-30-24 | Initiated | Goldman | Neutral |
| May-10-24 | Downgrade | TD Cowen | Buy → Hold |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Mar-29-23 | Initiated | UBS | Neutral |
| Jan-06-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-05-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-03-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-19-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-15-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Dec-12-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jun-24-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-04-22 | Downgrade | Goldman | Neutral → Sell |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-18-22 | Reiterated | KeyBanc Capital Markets | Overweight |
| Feb-18-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-18-22 | Reiterated | Raymond James | Outperform |
| Feb-18-22 | Reiterated | Stifel | Buy |
| Feb-18-22 | Reiterated | UBS | Neutral |
| Feb-18-22 | Reiterated | Wells Fargo | Overweight |
| Feb-11-22 | Initiated | Goldman | Neutral |
| Jan-07-22 | Resumed | Citigroup | Buy |
| Jan-07-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-13-21 | Upgrade | Cowen | Market Perform → Outperform |
| Sep-03-21 | Upgrade | Barclays | Equal Weight → Overweight |
| May-25-21 | Initiated | Barclays | Equal Weight |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-06-21 | Downgrade | UBS | Buy → Neutral |
| Dec-15-20 | Downgrade | Goldman | Buy → Neutral |
| Oct-01-20 | Upgrade | Citigroup | Neutral → Buy |
| Sep-04-20 | Downgrade | Argus | Buy → Hold |
| Jun-24-20 | Initiated | Oppenheimer | Outperform |
| Mar-19-20 | Upgrade | Stifel | Hold → Buy |
| Mar-18-20 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-05-20 | Initiated | Citigroup | Neutral |
| Feb-13-20 | Initiated | Goldman | Buy |
| Jan-02-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-17-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-26-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Apr-08-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Jan-02-19 | Upgrade | Citigroup | Neutral → Buy |
| Jan-02-19 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Nov-02-18 | Upgrade | Argus | Hold → Buy |
| Oct-16-18 | Initiated | Barclays | Underweight |
| May-17-18 | Resumed | Piper Jaffray | Overweight |
| Feb-06-18 | Reiterated | Citigroup | Neutral |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-03-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
View All
Baxter International Inc Stock (BAX) Latest News
Baxter International Inc. stock (US0673431090): Why does its hospital supply edge matter more now fo - AD HOC NEWS
Tiffany Zack joins Baxter as director of sustainability - Medical Buyer
Baxter International Inc stock (US0718131099): Is its medtech stability the real edge in uncertain m - AD HOC NEWS
Baxter Showcases Recent Innovations at AORN Global Surgical Conference and Expo 2026 - marketscreener.com
Baxter Showcases Recent Innovations at AORN Global Surgical Conference & Expo 2026 - National Today
Baxter Highlights New Surgical and Patient Support Products - National Today
Baxter International Inc. stock outperforms competitors on strong trading day - MarketWatch
Baxter Showcases Recent Innovations at AORN Global Surgical Conference & Expo 2026 (1) - PharmiWeb.com
BAX Showcases Innovative Products at Global Surgical Conference - GuruFocus
Gap Down: Is Baxter International Inc a cyclical or defensive stockQuarterly Growth Report & Growth Focused Investment Plans - baoquankhu1.vn
Short Squeeze: Is Baxter International Inc a cyclical or defensive stock2026 Macro Moves & Low Risk Growth Stock Ideas - baoquankhu1.vn
Baxter Launches Pilot Program for Therapy Animals in Healthcare Settings - respiratory-therapy.com
Baxter International Provides FY 2026 Earnings Guidance - National Today
Baxter (NYSE: BAX) exec holds 31K shares plus 25.9K options - Stock Titan
Baxter (NYSE: BAX) surgery chief lists common shares and option grants - Stock Titan
[Form 3] BAXTER INTERNATIONAL INC Initial Statement of Beneficial Ownership - Stock Titan
J&J Defends Blood-Clotting Powder IP From Baxter Attack - Law360
Robotic Pharmacy Prescription Market Research and Global Forecast Report 2025-2032 - GlobeNewswire Inc.
Baxter to Host First-Quarter 2026 Financial Results Conference Call for Investors - marketscreener.com
Baxter schedules April 30 webcast for first-quarter 2026 results - Stock Titan
Baxter International Inc (BAX) Stock Price, Trades & News - GuruFocus
Medical Syringe Market Is Booming So Rapidly Growth by 2033| - openPR.com
Hologic hires former Baxter International chief as next CEO - Radiology Business
Former Baxter chief takes helm at Marlborough medical device maker - The Business Journals
Baxter International Inc. (BAX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Fund Update: 3,614,465 BAXTER INTERNATIONAL (BAX) shares added to GREENHAVEN ASSOCIATES INC portfolio - Quiver Quantitative
Evercore ISI Group Lowers Price Target for Baxter International (BAX) to $22 | BAX Stock News - GuruFocus
Baxter Introduces the IV Verify Line Labeling System, an Automated Solution to Improve IV Labeling in Healthcare Settings - Bioscience Association Manitoba
Evercore ISI Adjusts Baxter International Price Target to $22 From $23, Maintains Outperform Rating - marketscreener.com
Evercore Maintains Baxter International Inc(BAX.US) With Buy Rating, Cuts Target Price to $22 - 富途牛牛
Assessing Baxter (BAX) Valuation After Launch Of IV Verify Line Labeling System - simplywall.st
Aug PreEarnings: Can Baxter International Inc deliver alphaEarnings Miss & Reliable Price Breakout Signals - baoquankhu1.vn
Does Baxter’s New IV Verify Labeling System Redefine Its Automation Edge In Healthcare Workflow Efficiency (BAX)? - Sahm
How Investors May Respond To Baxter International (BAX) Expanding Into Automated IV Line Labeling Systems - Yahoo Finance
BAXTER INTERNATIONAL INC. R (BTL.HM) Q2 FY2025 earnings call transcript - Yahoo Finance
Baxter International unveils IV Verify to enhance IV labeling accuracy - msn.com
List of 21 Acquisitions by Baxter (Apr 2026) - Tracxn
Columbia Intrinsic Value Fund's Baxter International Inc(BAX) Holding History - GuruFocus
Baxter’s IV Verify Launch Tests Medication Safety Strategy And Hospital Traction - simplywall.st
Baxter International Introduces IV Verify to Improve the Precision of IV Labeling - Bitget
Baxter International Unveils IV Verify to Enhance IV Labeling Accuracy - Yahoo Finance
Pet Partners, Baxter Foundation Expand Therapy Animal Programs for Patients, Healthcare Workers - Pet Age
Baxter (BAX) Unveils New IV Verify Line Labeling System for Nurs - GuruFocus
Baxter International Inc. stock outperforms competitors despite losses on the day - MarketWatch
Baxter International Hits New 52-Week Low at $15.87 - Markets Mojo
Baxter International Inc (BAX) Stock Price Down 4.2% on Mar 30 - GuruFocus
Baxter launches IV labeling system aimed at improving safety, efficiency - Medical Economics
Pet Partners and the Baxter Foundation Expand Therapy Animal Programs to Support 100,000 Patients and Healthcare Workers in Two-Year Pilot - Bioscience Association Manitoba
Baxter debuts automated IV line labeling system By Investing.com - in.investing.com
Baxter debuts automated IV line labeling system - Investing.com
Baxter Foundation Therapy Animal Push And What It Means For Investors - Sahm
Baxter International Inc Stock (BAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.39%
0.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):